Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Blackstone Emerges As Likely Buyer For Takeda's OTC Business At Price Close To $3Bn

Aug 20 2020

• By Ian Haydock

Takeda HQ

Related Content

Ferring And Blackstone Launch Gene Therapy Company

Nov 25 2019

Alnylam Secures $2bn Financing From Blackstone By Monetizing Inclisiran Royalties

Apr 13 2020

Blackstone Bets On Pharma In First Japan Buy, But Why?

Mar 27 2019

Related Companies

Takeda Pharmaceutical Co. Ltd.

Shire Pharmaceuticals Group PLC

Taisho Pharmaceutical Co., Ltd.

Theramex

Medtronic plc

Ferring Pharmaceuticals

Alnylam Pharmaceuticals Inc.

Nycomed GmbH

Alinamin Pharmaceutical Co., Ltd.

Additional Topics

International Japan Asia Pacific United States Manufacturing OTC Drugs Commercial Business Strategies Companies Deals Financing M & A OTC Devices Consumer

More from Manufacturing

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window